Stockscreener 앱 받기
5.84
7.89%
-0.50
시간 외 거래:
5.91
0.07
+1.20%
전일 마감가:
$6.34
열려 있는:
$6.34
하루 거래량:
1.57M
Relative Volume:
0.82
시가총액:
$439.87M
수익:
$13.38M
순이익/손실:
$-241.11M
주가수익비율:
-1.3714
EPS:
-4.2584
순현금흐름:
$-140.93M
1주 성능:
-7.01%
1개월 성능:
-17.86%
6개월 성능:
-28.87%
1년 성능:
-3.95%
1일 변동 폭
$5.80
$6.365
1주일 범위
$5.80
$6.805
52주 변동 폭
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.84 | 477.53M | 13.38M | -241.11M | -140.93M | -4.2584 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-04 | 개시 | H.C. Wainwright | Buy |
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
VSTM: Strong sales, robust clinical progress, and major data updates expected mid-year - TradingView
FY2025 EPS Estimates for Verastem Increased by HC Wainwright - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
HC Wainwright Forecasts Verastem FY2025 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Verastem Extends Cash Runway and Highlights 2025 Results - The Globe and Mail
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 970 Shares - GuruFocus
HC Wainwright Estimates Verastem FY2030 Earnings - MarketBeat
VSTM: HC Wainwright & Co. Assumes 'Buy' Rating with Price Target of $18.00 | VSTM Stock News - GuruFocus
Verastem Oncology: Preliminary Q4/2025 Revenue and Business Updates; 2026 Priorities for Novel RAS/MAPK Pathway-Driven Cancer Portfolio - marketscreener.com
Verastem Projects $17.5 Million Net Revenue for Q4 2025 - Intellectia AI
Verastem (VSTM) Makes Strides with Innovative Cancer Treatments - GuruFocus
Verastem (NASDAQ:VSTM) Now Covered by HC Wainwright - MarketBeat
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target - Investing.com Nigeria
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target - Investing.com Canada
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target By Investing.com - Investing.com South Africa
Verastem reports $17.5 million in Q4 revenue for cancer treatment By Investing.com - Investing.com Canada
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - ChartMill
RBC Capital Remains a Buy on Verastem (VSTM) - The Globe and Mail
Verastem, Inc. (VSTM): Investor Outlook With A Potential Upside Of 151.56% - DirectorsTalk Interviews
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Cantech Letter
ETF Watch: Is Verastem Inc forming a double bottomWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks
Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Have Verastem Insiders Been Selling Stock? - simplywall.st
CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus
Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat
Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 10,321 Shares of Stock - MarketBeat
EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ
Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM) - The Globe and Mail
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill
Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus
Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - DirectorsTalk Interviews
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):